H
Howard S. Hochster
Researcher at Rutgers University
Publications - 335
Citations - 18573
Howard S. Hochster is an academic researcher from Rutgers University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 57, co-authored 312 publications receiving 15743 citations. Previous affiliations of Howard S. Hochster include University of California, San Francisco & Yale Cancer Center.
Papers
More filters
Journal ArticleDOI
VEGF inhibition and renal thrombotic microangiopathy.
Vera Eremina,J. Ashley Jefferson,Jolanta Kowalewska,Howard S. Hochster,Mark Haas,Joseph Weisstuch,Catherine A. Richardson,Jeffrey B. Kopp,M. Golam Kabir,Peter H. Backx,Hans-Peter Gerber,Napoleone Ferrara,Laura Barisoni,Charles E. Alpers,Susan E. Quaggin +14 more
TL;DR: To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, this work used conditional gene targeting to delete V EGF from renal podocytes in adult mice and resulted in a profound thromBotic glomerular injury.
Journal ArticleDOI
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson,Alan P. Venook,Lynette Cederquist,Emily Chan,Yi-Jen Chen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Peter C. Enzinger,Alessandro Fichera,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Mary F. Mulcahy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Christina Wu,Kristina M. Gregory,Deborah A. Freedman-Cass +32 more
TL;DR: This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease and considers treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences.
Journal ArticleDOI
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio Garcia-Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Eveline Boucher,Marc Peeters,Ben Tran,Heinz-Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu +23 more
TL;DR: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival, and this phase 3 trial was the first to report this result.
Journal ArticleDOI
Rectal cancer, version 2.2018 clinical practice guidelines in Oncology
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Lynette Cederquist,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Mary F. Mulcahy,James D. Murphy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Evan Wuthrick,Deborah A. Freedman-Cass,Kristina M. Gregory,Lisa A. Gurski +35 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survivorship in patients with rectal cancer.
Journal ArticleDOI
NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Lynette Cederquist,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Ignacio Garrido-Laguna,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Evan Wuthrick,Kristina M. Gregory,Deborah A. Freedman-Cass +35 more
TL;DR: The NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib are summarized.